CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 51 enrolled
Drug / intervention
Octreotide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03289741
NCT03289741Phase 4Completed
CompareCT.gov

A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center·interventional·Posted Sep 21, 2017·Updated May 9, 2025

In Brief

A Phase 4 clinical trial evaluating Octreotide, LAR Lanreotide, and 1 other intervention for Neuroendocrine Tumors. Completed, enrolled 51 participants across 7 sites.

Detailed Summary

This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedSep 21, 2017
Enrollment StartSep 19, 2017
Primary CompletionApr 10, 2023
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 8.8 years ago

Interventions

Octreotidedrug

Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections

LAR Lanreotidedrug

Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections

Questionnairesbehavioral

Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.